聚维酮碘口腔抗菌漱口液快速灭活严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)。
Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse.
机构信息
Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT.
Ocean Ophthalmology Group, Miami, FL.
出版信息
J Prosthodont. 2020 Jul;29(6):529-533. doi: 10.1111/jopr.13209. Epub 2020 Jun 16.
PURPOSE
To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone-iodine (PVP-I) against SARS-CoV-2 ('corona virus') to mitigate the risk and transmission of the virus in the dental practice.
MATERIALS AND METHODS
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) USA-WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone-iodine (PVP-I) as the sole active ingredient. The PVP-I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end-point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated.
RESULTS
PVP-I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS-CoV-2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS-CoV-2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact.
CONCLUSIONS
PVP-I oral antiseptic preparations rapidly inactivated SARS-CoV-2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP-I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP-I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID-19 pandemic.
目的
研究聚维酮碘（PVP-I）口腔制剂对 SARS-CoV-2（“冠状病毒”）的杀病毒活性的最佳接触时间和浓度，以降低牙科实践中病毒的风险和传播。
材料和方法
使用含有聚维酮碘（PVP-I）作为唯一活性成分的口腔抗菌溶液对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）美国-WA1/2020 株病毒株进行测试。PVP-I 以 0.5%、1%和 1.5%的稀释浓度进行测试。将不含任何病毒的试验介质添加到 2 管化合物中，作为毒性和中和对照。乙醇（70%）作为阳性对照平行测试，仅用水作为阴性对照。试验溶液和病毒在室温（22±2°C）下孵育 15 和 30 秒。然后，通过在最小必需培养基（MEM）2%胎牛血清（FBS）、50µg/mL 庆大霉素中进行 1/10 稀释将溶液中和。通过标准终点稀释测定法对每个样品中的存活病毒进行定量，并计算每个化合物与阴性（水）对照相比的对数减少值（LRV）。
结果
所有测试浓度（0.5%、1%和 1.5%）的 PVP-I 口腔抗菌剂在接触 15 秒内即可完全灭活 SARS-CoV-2。70%乙醇对照组在接触 15 秒内无法完全灭活 SARS-CoV-2，但在接触 30 秒时能够灭活病毒。
结论
PVP-I 口腔抗菌制剂可快速在体外灭活 SARS-CoV-2 病毒。最低浓度为 0.5%PVP-I，最短接触时间为 15 秒，即可发挥杀菌活性。这一重要发现可以证明，在 COVID-19 大流行期间，对患者和医护人员进行术前口腔冲洗（用 PVP-I 冲洗）可能有用，可作为个人防护设备的辅助手段，适用于牙科和外科专业。
Zotero 插件